Scott S. Brooks – Chief Executive Officer
Mr. Brooks is President, Chief Executive Officer, and on the Board of Directors. Scott joined Regenesis Biomedical in January 2012 as the Chief Operating Officer. He has held senior executive positions in four major healthcare organizations. Scott has extensive experience in sales, marketing, and operations. Prior to Regenesis he held the position of President in the U.S. and Canada for BSN Medical located in Charlotte, NC. At BSN Scott was instrumental in developing sales, expanding clinical education programs, and enhancing management development. Prior to BSN, Scott was the VP of Sales and National Accounts for Kinetic Concepts Inc. (KCI), the global leader of advanced wound care devices. During his tenure at KCI, he held senior leadership positions in five different divisions of the company. KCI’s broad device portfolio includes therapy devices designed for advanced wound care, critical care and bariatric care, sold throughout the continuum of care. Scott served on the senior management team as the company emerged into the innovative global leader in advance wound care. He was also instrumental in two mergers and acquisitions, plus negotiated and implemented numerous strategic contracts and alliances. Scott’s experience also includes successful leadership positions with The Hill-Rom Company and Kimberly-Clark Healthcare. Mr. Brooks earned a Bachelor of Arts in Business Administration from Western Washington University.
Brian Mower – Vice-President and Chief Financial Officer
Mr. Mower joined Regenesis Biomedical in 2018, bringing 20+ years of executive financial leadership with a focus on commercializing innovative medical device technologies. Brian has successfully helped multiple companies obtain regulatory clearances, grow revenue, improve profitability, and increase shareholder value. He was recognized as the 2018 Minneapolis-Saint Paul Business Journal CFO of the year. He previously was CFO for Medibio Limited, an Australian public company. During his time there, he helped relocate international headquarters to Minneapolis, attain dual trading capacity, and obtain key regulatory clearances. He spent 8 years at Torax Medical (acquired by Johnson & Johnson), an implantable medical device technology firm, leading finance and international sales operations. Through regulatory clearances and high growth sales, he helped Torax grow from a pre-clinical start-up stage into a firm with 200+ hospital customers in 8 countries, before leading the successful acquisition by Ethicon, a J&J company. Brian also held CFO roles at other companies, including: Iomed, Inc., a publicly traded drug delivery company acquired by ReAble Therapeutics; EMPI, a pain management company acquired by DJO Global; and of DJO Global, an orthopedic and rehabilitation medical device firm. Mr. Mower began his career in the international accounting firm KPMG, is a Certified Public Accountant, and has memberships in the AICPA and UACPA organizations. He received both Bachelor of Science and Master of Accountancy degrees from Brigham Young University.
Tom Eisiminger, Jr. – Vice-President, Sales
Mr. Eisiminger is a retired United States Army Officer and decorated combat veteran. He joined Regenesis in 2006 after a short tenure with GlaxoSmithKline, initially serving as Clinical Support and Territory Manager, then Northwest Regional Sales Director and Vice President of Sales. Tom held numerous leadership positions in the Army from platoon to battalion command. He managed the largest geographically dispersed Army Recruiting Battalion responsible for operations in SW Washington, Oregon, Northern California, Hawaii, Korea, Japan, Guam, American Samoa, Commonwealth of the Northern Marianas Islands, and the Freely Associated States of the Republic of the Marshall Island, Republic of Palau and the Federated States of Micronesia. He twice earned awards as top recruiting unit in the Army. He earned his B.S. from the U. S. Military Academy at West Point, his M.A. in National Security and Strategic Studies from the Naval War College, and his M.B.A. from Marylhurst University in Portland, Oregon. Tom is a member of the Veterans of Foreign Wars, the American Legion, and the Disabled American Veterans. He is a veteran’s advocate and serves on the Board of Advisors and acts as Chairman of the Southwest Region AdvaMed Veterans Program (MVP) where he mentors transitioning veterans interested in joining the medical technology industry. A former Board member of several veteran non-profits, he is also a member of the Arizona Veterans Hall of Fame Class of 2018. He currently serves on the Board of Directors of the American Diabetes Association (ADA) – Arizona & New Mexico.
Scott Robey – Vice-President, Marketing
Mr. Robey is a 20+ year marketing veteran. Prior to Regenesis he served as Senior Director of Marketing at Kinetic Concepts, Inc (KCI) for the V.A.C. Therapy brand during the time US product sales grew from about $70M in 2000 to about $1 billion by 2007. He has held marketing positions at Medtronic, Sulzer Carbomedics, and Burron Medical (B. Braun Medical, Inc). His responsibilities have included product management, new product development and commercialization, branding, clinical education programs, and key opinion leader and society relationship development. Mr. Robey has an M.S. in Management from Purdue University, and a B.S. in Biomedical Engineering from Louisiana Tech University.
Randy Chavez – Vice-President, Regulatory Affairs and Quality Assurance
Mr. Chavez brings 20 years experience to the Regulatory and Quality role at Regenesis. He came aboard in 2008 with a successful track record of implementing Quality Management Systems and OUS applications for the EU, Canadian and Australian market approvals. His work at Regenesis has involved remediation and upgrade of the Quality Management System to FDA and ISO standards to bring the company forward from a specification developer to a manufacturer of the Provant Therapy System. His key projects at Regenesis involved multiple 510(k) submissions, release of an upgraded model of the Provant Therapy System, reclassification of the Provant from a Pre-Amendments Class III device to a Class II device and CE Marking for expanded indications. Mr. Chavez has an B.S. in Chemical Engineering from Arizona State University (ASU) and is currently enrolled ASU for his M.S. degree in Regulatory Science.